FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149169512> ?p ?o ?g. }

• W2149169512 endingPage "1672" @default.
• W2149169512 startingPage "1662" @default.
• W2149169512 abstract "// Bryce P Portier 1 , Eugen C Minca 2 , Zhen Wang 2 , Christopher Lanigan 2 , Aaron M Gruver 2 , Erinn Downs-Kelly 2 , G Thomas Budd 3 , and Raymond R Tubbs 2 1 Department of Pathology and Genomic Medicine, Houston Methodist, Houston, TX 2 Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH 3 Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Correspondence: Bryce P. Portier, email: // Keywords : Breast carcinoma, HER2, HER4, Immunohistochemistry, RT-qPCR, Trastuzumab, H-Score Received : July 31, 2013 Accepted : August 24, 2013 Published : August 26, 2013 Abstract Prognostic and predictive markers utilized in invasive breast carcinoma are limited and include ER, PR, Ki67, and ERBB2 (HER2). In the case of HER2, over-expression or amplification serves as eligibility for anti-HER2 based therapy, including trastuzumab (Herceptin®, Genentech). While clinical trials have shown trastuzumab improves overall survival and time to progression, an individual’s response to anti-HER2 based therapy is highly variable. This suggests that, in a “uniform” HER2 positive population, additional markers could help in predicting patient outcome to therapy. Here we utilized a recently validated high-specificity HER4 antibody (E200) and generated a standard clinical HER4 scoring algorithm (HER4 H-Score) utilizing two breast carcinoma cohorts: 1) patients receiving neoadjuvant trastuzumab (n=47) and 2) patients receiving trastuzumab for metastatic disease (n=33). Our HER4 H-Score showed significant correlation with high sensitivity RT-qPCR performed on matched patients (p=<0.0001). In addition, patients with HER2/HER4 co-over-expression status showed a significant delay in development of metastasis after neo-adjuvant trastuzumab therapy (p= 0.04) and showed a significant improvement in progression free survival after adjuvant trastuzumab therapy (p=0.03). These findings suggest HER4 IHC, used in conjunction with a standard HER2 testing algorithm, could aid in predicting clinical outcome and help identify patients likely to show improved response to trastuzumab therapy." @default.
• W2149169512 created "2016-06-24" @default.
• W2149169512 creator A5020502594 @default.
• W2149169512 creator A5021235748 @default.
• W2149169512 creator A5030476275 @default.
• W2149169512 creator A5038563648 @default.
• W2149169512 creator A5044574148 @default.
• W2149169512 creator A5052850223 @default.
• W2149169512 creator A5059707915 @default.
• W2149169512 creator A5081535615 @default.
• W2149169512 date "2013-08-26" @default.
• W2149169512 modified "2023-09-27" @default.
• W2149169512 title "HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma" @default.
• W2149169512 cites W1644299043 @default.
• W2149169512 cites W1784466036 @default.
• W2149169512 cites W1895627253 @default.
• W2149169512 cites W1985620074 @default.
• W2149169512 cites W1997567558 @default.
• W2149169512 cites W2007435673 @default.
• W2149169512 cites W2016397937 @default.
• W2149169512 cites W2028061086 @default.
• W2149169512 cites W2040613517 @default.
• W2149169512 cites W2054159503 @default.
• W2149169512 cites W2060372515 @default.
• W2149169512 cites W2063350213 @default.
• W2149169512 cites W2073282855 @default.
• W2149169512 cites W2080661875 @default.
• W2149169512 cites W2090855460 @default.
• W2149169512 cites W2094313894 @default.
• W2149169512 cites W2099010186 @default.
• W2149169512 cites W2107038774 @default.
• W2149169512 cites W2109817042 @default.
• W2149169512 cites W2115736838 @default.
• W2149169512 cites W2122788299 @default.
• W2149169512 cites W2123415105 @default.
• W2149169512 cites W2130900820 @default.
• W2149169512 cites W2138899227 @default.
• W2149169512 cites W2140840142 @default.
• W2149169512 cites W2141393790 @default.
• W2149169512 cites W2155614211 @default.
• W2149169512 cites W2166655074 @default.
• W2149169512 cites W2169099750 @default.
• W2149169512 cites W2318605753 @default.
• W2149169512 doi "https://doi.org/10.18632/oncotarget.1232" @default.
• W2149169512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3858553" @default.
• W2149169512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24091566" @default.
• W2149169512 hasPublicationYear "2013" @default.
• W2149169512 type Work @default.
• W2149169512 sameAs 2149169512 @default.
• W2149169512 citedByCount "21" @default.
• W2149169512 countsByYear W21491695122014 @default.
• W2149169512 countsByYear W21491695122015 @default.
• W2149169512 countsByYear W21491695122016 @default.
• W2149169512 countsByYear W21491695122017 @default.
• W2149169512 countsByYear W21491695122018 @default.
• W2149169512 countsByYear W21491695122019 @default.
• W2149169512 countsByYear W21491695122020 @default.
• W2149169512 countsByYear W21491695122021 @default.
• W2149169512 countsByYear W21491695122022 @default.
• W2149169512 crossrefType "journal-article" @default.
• W2149169512 hasAuthorship W2149169512A5020502594 @default.
• W2149169512 hasAuthorship W2149169512A5021235748 @default.
• W2149169512 hasAuthorship W2149169512A5030476275 @default.
• W2149169512 hasAuthorship W2149169512A5038563648 @default.
• W2149169512 hasAuthorship W2149169512A5044574148 @default.
• W2149169512 hasAuthorship W2149169512A5052850223 @default.
• W2149169512 hasAuthorship W2149169512A5059707915 @default.
• W2149169512 hasAuthorship W2149169512A5081535615 @default.
• W2149169512 hasBestOaLocation W21491695121 @default.
• W2149169512 hasConcept C121608353 @default.
• W2149169512 hasConcept C126322002 @default.
• W2149169512 hasConcept C143998085 @default.
• W2149169512 hasConcept C204232928 @default.
• W2149169512 hasConcept C2778292576 @default.
• W2149169512 hasConcept C2779786085 @default.
• W2149169512 hasConcept C2908647359 @default.
• W2149169512 hasConcept C3018521938 @default.
• W2149169512 hasConcept C530470458 @default.
• W2149169512 hasConcept C71924100 @default.
• W2149169512 hasConcept C99454951 @default.
• W2149169512 hasConceptScore W2149169512C121608353 @default.
• W2149169512 hasConceptScore W2149169512C126322002 @default.
• W2149169512 hasConceptScore W2149169512C143998085 @default.
• W2149169512 hasConceptScore W2149169512C204232928 @default.
• W2149169512 hasConceptScore W2149169512C2778292576 @default.
• W2149169512 hasConceptScore W2149169512C2779786085 @default.
• W2149169512 hasConceptScore W2149169512C2908647359 @default.
• W2149169512 hasConceptScore W2149169512C3018521938 @default.
• W2149169512 hasConceptScore W2149169512C530470458 @default.
• W2149169512 hasConceptScore W2149169512C71924100 @default.
• W2149169512 hasConceptScore W2149169512C99454951 @default.
• W2149169512 hasIssue "10" @default.
• W2149169512 hasLocation W21491695121 @default.
• W2149169512 hasLocation W21491695122 @default.
• W2149169512 hasLocation W21491695123 @default.
• W2149169512 hasLocation W21491695124 @default.
• W2149169512 hasOpenAccess W2149169512 @default.
• W2149169512 hasPrimaryLocation W21491695121 @default.

• next